pocketful logo light
pocketful logo light
Aurobindo Pharma Ltd logo

Aurobindo Pharma Ltd

NSE: AUROPHARMA BSE: 524804

₹1713.40

(1.19%)

Tue, 22 Sept 2026, 05:32 pm

mtf coin illustrationMTF 5x

Aurobindo Pharma Share Price Live Chart

1 Day

(1.19%)

No Result Found

Summary

  • Market Cap (in Cr)

    83106.9

  • Net Profit (in Cr)

    3483.57

  • P/B

    2.06

  • Sector P/E

    33.76

  • P/E

    19.32

  • EV/EBITDA

    9.39

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    11.15

  • ROCE

    14.16

  • Debt/Equity

    0.24

  • EPS (TTM)

    61.09

  • Dividend Yield

    0

  • Book Value

    652.39

  • Interest Cover

    12.08

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters51.8251.8251.8251.8251.82
FII15.2413.9414.2114.3715.33
DII25.8727.6827.6026.9326.23
Public7.086.556.386.876.61
Government0000.000.00

Read More

Technical Analysis

RSI

56.69

MACD

22.30

50 DMA

1623.08

200 DMA

1397.24

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic2017.331837.131777.071656.931596.871476.731296.53
Fibonacci1837.131768.301725.771656.931588.101545.571476.73
Camarilla1766.561750.041733.521656.931700.481683.961667.44

Pivots Level: Classic

R3

+360.40

2017.33

R2

+180.20

1837.13

R1

+120.13

1777.07

1656.93
1656.93
Pivot Point
LTP: 1700

S1

-60.07

1596.87

S2

-180.20

1476.73

S3

-360.40

1296.53

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1688.47

  • 20-EMA

    1671.72

  • 30-EMA

    1656.48

  • 50-EMA

    1626.59

  • 100-EMA

    1554.00

  • 200-EMA

    1446.19

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
21 May 2026board-meetingsAccounts
06 Apr 2026buyback
09 Feb 2026board-meetingsQuarterly Results, Nine Months Results
05 Nov 2025board-meetingsQuarterly Results
12 Aug 2025agm
04 Aug 2025dividend₹4.00 Dividend /Share08 Aug 2025
08 Jul 2025dividendInterim Dividend - Rs. - 408 Aug 2025
30 Jul 2024agm
26 Jul 2024agmAnnual General Meeting27 Aug 2024
18 Jul 2024buyback

Read More

Peer Comparison

Aurobindo Pharma Ltd logo

Aurobindo Pharma Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Aurobindo Pharma Ltd About

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1986

Headquarters

CEO

M R Kumar

Employees

Contact

Website icon

Website

http://www.aurobindo.com

Email icon

Email

cs@aurobindo.com; investorgrievances@aurobindo.com

Phone icon

Phone

91-40-23736370

Location icon

Location

Plot No 2 Maitrivihar, Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, 500038

Read More

Aurobindo Pharma Ltd Company History

YearHistory
2020
  • Tied up with BIRAC to develop COVID-19 vaccine.
  • Collaborated with CSIR to develop COVID-19 vaccine.
  • Signed exclusive licensing agreement with COVAXX.
2021
  • Received USFDA approval for Droxidopa Capsules.
  • Received NCLT approval for scheme of amalgamation.
2022
  • Acquired 51% stake in GLS Pharma Limited.
  • Arm received final USFDA approval for Vasopressin injection.
  • Arm received USFDA approval for Triamcinolone Acetonide injectable suspension.
2023
  • Arm received USFDA approval for cancer drug.
  • To launch HIV triple combination product for children under ViiV Healthcare licence.
2024
  • Received first USFDA approval for Lidocaine Hydrochloride Injection.
  • Commissioned four plants in Andhra Pradesh including Pen-G facility.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GOLDMAN SACHS (SINGAPORE) PTE.- ODIblockSell106228110716 Oct 2025
GOLDMAN SACHS BANK EUROPESE - ODIblockBuy106228110716 Oct 2025
MARSHALL WACE INVESTMENT STRATEGIES SYSTEMATIC ALPHA PLUS FUNDblockBuy8621160.125 Jan 2024
SOCIETE GENERALEblockSell1075581160.125 Jan 2024
SOCIETE GENERALEblockBuy14843231160.125 Jan 2024
BNP PARIBAS ARBITRAGEblockSell14843231160.125 Jan 2024
MARSHALL WACE INVESTMENT STRATEGIES EUREKA FUNDblockBuy536411160.125 Jan 2024
MARSHALL WACE INVESTMENT STRATEGIES - EUREKA FUNDblockBuy1064801160.125 Jan 2024
MARSHALL WACE INVESTMENT STRATEGIES MARKET NEUTRAL TOPS FUNDblockBuy81341160.125 Jan 2024
MARSHALL WACE INVESTMENT STRATEGIESGTOPS FUNDblockBuy275711160.125 Jan 2024

Read More

Aurobindo Pharma Ltd News

Aurobindo Pharma to host JP Morgan analyst meet

Aurobindo Pharma officials will participate in a group investor meeting with JP Morgan on September 24, 2026, in Hyderabad. No UPSI will be discussed.

21 Sept 2026

companies

Aurobindo Pharma gets USFDA nod for Beclomethasone HFA

Aurobindo Pharma secured USFDA final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol in 40 mcg and 80 mcg strengths, its first MDI product, in a US market worth $301 million.

15 Sept 2026

companies

Aurobindo Pharma acquires A1 Biochem USA stake

Aurobindo Pharma completes acquisition of 100% stake in newly incorporated A1 Biochem USA Inc for $1 million to expand CRO services.

12 Sept 2026

companies

Aurobindo Pharma unit clears US FDA inspection cleanly

Aurobindo Pharma's subsidiary Apitoria's Unit-IV API facility completed a US FDA inspection with no observations or issues raised, signalling regulatory compliance.

11 Sept 2026

companies

Aurobindo Pharma to attend Bank of America Asia Pacific conference

Aurobindo Pharma officials will participate in the Bank of America 2026 Asia Pacific Conference in Hong Kong on September 21, 2026. The company confirmed that no unpublished price-sensitive information will be discussed during the scheduled one-on-one and group meetings.

11 Sept 2026

companies

Read More

Frequently Asked Questions

  • 1.What is the stock price of Aurobindo Pharma Ltd?

    As of 22/09/2026 at 11:02 PM, Aurobindo Pharma Ltd shares are trading at ₹1713.40.

  • 2.What is the market cap. of Aurobindo Pharma Ltd?

    As of 22/09/2026, the market capitalization of Aurobindo Pharma Ltd is ₹99,828.06 crore.

  • 3.When was Aurobindo Pharma Ltd founded?

    Aurobindo Pharma Ltd was founded in 1986.

  • 4.What are the P/E and P/B ratios of Aurobindo Pharma Ltd?

    As of 22/09/2026, Aurobindo Pharma Ltd has a P/E ratio of 26.77 and a P/B ratio of 2.06.

  • 5.How can I buy shares of Aurobindo Pharma Ltd?

    You can buy shares of Aurobindo Pharma Ltd through Pocketful. Simply open a Demat account, complete your KYC, add funds, and place a buy order.

  • 6.What is the shareholding pattern of Aurobindo Pharma Ltd?

    As of March,2026, promoters hold 51.82% in Aurobindo Pharma Ltd, while FIIs, DIIs and public shareholders hold 15.24%, 25.87% and 7.08%, respectively.

  • 7.Does Aurobindo Pharma Ltd pay dividends?

    Yes, Aurobindo Pharma Ltd pays dividends to eligible shareholders. The latest dividend announced by the company was ₹₹4.00 Dividend /Share per share.

  • 8.What is the dividend yield of Aurobindo Pharma Ltd?

    As of 22 September, 2026, the dividend yield of Aurobindo Pharma Ltd stands at 0.23%.

  • 9.What are the latest financial results of Aurobindo Pharma Ltd?

    For January,2024, Aurobindo Pharma Ltd reported revenue of ₹31,403.00 crore and a net profit of ₹3,486.00 crore.

  • 10.What is the Stock symbol of Aurobindo Pharma Ltd?

    AUROPHARMA is the stock symbol of Aurobindo Pharma Ltd.

  • 11.Who is the CEO of Aurobindo Pharma Ltd?

    The CEO of Aurobindo Pharma Ltd is M R Kumar.

Open Your Free Demat Account

Enter your phone number